Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER
Status: Enrolling
Updated:  12/14/2016
Sylvester Cancer Center, University of Miami
mi
from
Miami, FL
Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer
A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER
Status: Enrolling
Updated: 12/14/2016
Sylvester Cancer Center, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
Phase I/II Study to Evaluate Combined Hyperfractionated Radiation Therapy and 5-Fluorouracil, Cisplatin and Paclitaxel (Taxol) and Amifostine (WR 2721, Ethyol) in Stage III and IV Inoperable Head and Neck Carcinomas
Status: Enrolling
Updated:  12/14/2016
Sylvester Cancer Center, University of Miami
mi
from
Miami, FL
Radiation Therapy, Combination Chemotherapy, and Amifostine in Treating Patients With Head and Neck Cancer
Phase I/II Study to Evaluate Combined Hyperfractionated Radiation Therapy and 5-Fluorouracil, Cisplatin and Paclitaxel (Taxol) and Amifostine (WR 2721, Ethyol) in Stage III and IV Inoperable Head and Neck Carcinomas
Status: Enrolling
Updated: 12/14/2016
Sylvester Cancer Center, University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  12/14/2016
Abraxis BioScience, Inc.
mi
from
Raleigh, NC
ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer
A Phase II Clinical Trial of ABI-007 (A Cremophor-Free, Protein Stabilized, Nanoparticle Paclitaxel)Administered Weekly in Taxol Resistant Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 12/14/2016
Abraxis BioScience, Inc.
mi
from
Raleigh, NC
Click here to add this to my saved trials
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
An Open-label, Phase I/II Trial of ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle, Paclitaxel) Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/14/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With a Fixed Dose of Cisplatin Concomitant With Definitive Radiation in Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
Status: Enrolling
Updated:  12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
Translational Phase I Trial of Escalating Doses of 5-Chloro-2'-Deoxycytidine (CldC) With a Fixed Dose of Tetrahydrouridine Combined With a Fixed Dose of Cisplatin Concomitant With Definitive Radiation in Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
Status: Enrolling
Updated: 12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated:  12/14/2016
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Phase II Study of Oxaliplatin in Combination With Gemcitabine for 2 Line Treatment of NSCLC Patients With Advanced and Metastatic Disease
Status: Enrolling
Updated: 12/14/2016
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine
Status: Enrolling
Updated:  12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer
Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine
Status: Enrolling
Updated: 12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery
A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Pilot Study of Gemcitabine, Oxaliplatin, and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Pilot Study of Gemcitabine, Oxaliplatin, and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
Carboplatin and Irinotecan Concomitantly With Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel for Locally Advanced Non-Small Cell Lung Cancer (GIA 12177).
Status: Enrolling
Updated:  12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Carboplatin, Irinotecan, and Radiation Therapy Followed By Docetaxel in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer
Carboplatin and Irinotecan Concomitantly With Radiation Therapy Followed by Consolidation Chemotherapy With Docetaxel for Locally Advanced Non-Small Cell Lung Cancer (GIA 12177).
Status: Enrolling
Updated: 12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
A Phase I Study of 5-FU (Plus Leucovorin) and Arsenic Trioxide for Patients With Refractory/Relapsed Metastatic Colorectal Carcinoma
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity
Status: Enrolling
Updated:  12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery
A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity
Status: Enrolling
Updated: 12/14/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026)
Status: Enrolling
Updated:  12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Docetaxel and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer
A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026)
Status: Enrolling
Updated: 12/14/2016
University of Miami, Sylvester Comprehensive Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery
A Pilot Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery
Status: Enrolling
Updated:  12/14/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery
A Pilot Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery
Status: Enrolling
Updated: 12/14/2016
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine
Status: Enrolling
Updated:  12/15/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
Evaluation of CD8+ T Cell Activation and Infiltration Into Primary Breast Tumors Following Administration of a Peptide Vaccine
Status: Enrolling
Updated: 12/15/2016
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Status: Enrolling
Updated:  12/15/2016
University of Virginia
mi
from
Charlottesville, VA
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma
Status: Enrolling
Updated: 12/15/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  12/15/2016
Johns Hopkins University
mi
from
Baltimore, MD
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 12/15/2016
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  12/15/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 12/15/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  12/15/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 12/15/2016
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan
Status: Enrolling
Updated:  12/15/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan
Status: Enrolling
Updated: 12/15/2016
University of Maryland/Marlene and Stewart Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Status: Enrolling
Updated:  12/15/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer
Status: Enrolling
Updated: 12/15/2016
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of KCC Peptide Application in the Colon
Phase 1B Study of KCC Peptide Application in the Colon
Status: Enrolling
Updated:  12/15/2016
University of Michigan
mi
from
Ann Arbor, MI
Study of KCC Peptide Application in the Colon
Phase 1B Study of KCC Peptide Application in the Colon
Status: Enrolling
Updated: 12/15/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Preventive Health Behavior in Women
Preventive Health Behavior in Women
Status: Enrolling
Updated:  12/15/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Preventive Health Behavior in Women
Preventive Health Behavior in Women
Status: Enrolling
Updated: 12/15/2016
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer
Status: Enrolling
Updated:  12/19/2016
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
A Phase I/II Clinical Trial of the Anti-EGFR Monoclonal Antibody, Panitumumab, and the Proteosomal Inhibitor, Bortezomib, in Patients With Advanced, Refractory KRAS Wild-Type Colorectal Cancer
Status: Enrolling
Updated: 12/19/2016
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Status: Enrolling
Updated:  12/19/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Status: Enrolling
Updated: 12/19/2016
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Status: Enrolling
Updated:  12/19/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Status: Enrolling
Updated: 12/19/2016
Case Western Reserve Univ
mi
from
Cleveland, OH
Click here to add this to my saved trials
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Status: Enrolling
Updated:  12/19/2016
Academic Medical Center
mi
from
Amsterdam,
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management
Status: Enrolling
Updated: 12/19/2016
Academic Medical Center
mi
from
Amsterdam,
Click here to add this to my saved trials
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/19/2016
Massachusetts General Hospital
mi
from
Boston, MA
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/19/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/19/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/19/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase I Study of Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Locally Unresectable Non-Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study
Status: Enrolling
Updated:  12/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents
Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study
Status: Enrolling
Updated: 12/20/2016
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS)
Status: Enrolling
Updated:  12/22/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling
Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling (GPS)
Status: Enrolling
Updated: 12/22/2016
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Carolina Healthcare System
mi
from
Charlotte, NC
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
A Multi-center Phase I Trial of Temsirolimus in Combination With Valproic Acid in Children and Adolescents With Multiply Relapsed Pediatric Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Carolina Healthcare System
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Atlanta, GA
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/22/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1, First-In-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/22/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Study of Pazopanib and Vorinostat
A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
Status: Enrolling
Updated:  12/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase I Study of Pazopanib and Vorinostat
A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies
Status: Enrolling
Updated: 12/27/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Status: Enrolling
Updated:  12/28/2016
M D Anderson Cancer Center
mi
from
Houston, TX
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Status: Enrolling
Updated: 12/28/2016
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated:  12/28/2016
Pivotal Research Centers
mi
from
Peoria, AZ
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated: 12/28/2016
Pivotal Research Centers
mi
from
Peoria, AZ
Click here to add this to my saved trials
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated:  12/28/2016
Eastchester Center for Cancer Care
mi
from
Bronx, NY
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated: 12/28/2016
Eastchester Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated:  12/28/2016
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated: 12/28/2016
Mary Crowley Cancer Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated:  12/28/2016
British Columbia Cancer Agency
mi
from
Vancouver,
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Cancer Patients
Status: Enrolling
Updated: 12/28/2016
British Columbia Cancer Agency
mi
from
Vancouver,
Click here to add this to my saved trials
Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy
A Pilot Study of a Strength and Balance Training Program for Persons With Oxaliplatin Induced Peripheral Neuropathy
Status: Enrolling
Updated:  12/28/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Pilot Study of Strength and Balance Training Program for Persons With Oxaliplatin Induced Neuropathy
A Pilot Study of a Strength and Balance Training Program for Persons With Oxaliplatin Induced Peripheral Neuropathy
Status: Enrolling
Updated: 12/28/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials